Fig. 2. Antifungal drug use for inpatients stratified by the duration of antifungal drug use during each hospitalization period. A, aspergillosis; IPA, invasive pulmonary aspergillosis; PA, pulmonary aspergillosis; Vori-C, voriconazole; Itra-C, itraconazole; Flu-C, fluconazole; AmB, amphotericin B; EC, echinocandin

Korean J Clin Pharm 2023;33:113-21 https://doi.org/10.24304/kjcp.2023.33.2.113

© 2023 Korean J Clin Pharm